Tarsus Pharma Rg

Tarsus Pharma, a commercial‑stage biopharma from Irvine, targets unmet ocular conditions with XDEMVY treating blepharitis/Meibomian gland disease, plus TP‑04 for ocular rosacea and TP‑05 for Lyme disease and malaria prevention.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 323
HQ: Irvine

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
TARS	Tarsus Pharma Rg Cap: 3.3B	EQUITY	NMS	USD	US87650L1035	Active	📈